Global Toxoid Vaccines Market is valued at USD 4.97 Billion in 2021 and expected to reach USD 6.81 Billion by 2028 with a CAGR of 4.6% over the forecast period.
Global Toxoid Vaccines Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2022-2028- Increasing prevalence of tetanus and diphtheria, rising number of technological advancements, and growing supportive initiatives taken by the government are some of the major factors anticipated to drive the growth of Global Toxoid Vaccine Market.
Toxoid vaccines are used to induce an immune response against diseases caused by specific bacteria by using toxoids as antigens. The immunity against specific the body is able to form an immune response to the original toxin. This vaccine provides protection against tetanus in adults and children seven years or older. By utilizing toxoids, the body can shape an immune reaction to the first poison, yet since the toxoid is a debilitating type of toxoid, it can't prompt any toxicity or toxin-induced illness. Contrasted with different vaccines, toxoid vaccines are steadier and less defenseless to harm brought about by temperature, stickiness, or light. Generally, toxoid vaccines are given as a feature of a course of various dosages all through youth and adulthood for greatest security, and booster shots can be given in the event that are traveling to a high-hazard country for instance. Toxoid vaccines are more stable than compared to other vaccines. Toxoid vaccines are extremely effective and safe vaccines for tetanus and diphtheria. Vaccinations against these diseases are given as part of routine childhood vaccinations and have resulted in over 90-95% drop in cases and deaths worldwide since their introduction. A successful toxoid vaccine created in 1938 and used to prevent tetanus in the military during World War II.
The Covid-19 pandemic has also impacted the growth of global toxoid vaccines market. Unplanned disruption in all areas of life, including the delivery of health services like vaccinations were affected during pandemic. Vaccination drive for toxoid vaccines slowed down due to lockdown and focus of healthcare industry has shifted on Covid-19. Thus, the toxoid vaccines market negatively impacted during COVID -19 pandemic.
Some of the key players for global toxoid vaccines market are
The global toxoid vaccines market is segmented into on the basis of type, indication, distribution channel, application, end-user and region & country level. On the basis of type, the global toxoid vaccines market is segmented into monovalent tetanus toxoid (TT), tetanus-diphtheria (Td), diphtheria, tetanus, Pertussis (DTaP) and others. On the basis of indication, the market is classified into Tetanus, Pertussis, Diphtheria and others. On the basis of distribution channel, the global toxoid vaccines market is segmented into hospital pharmacy, retail pharmacy and online pharmacy. On the basis of application, the market is segmented into neonatal and adult. On the basis of end-user, the global toxoid vaccines market is classified into hospitals, specialty centers and others.
The regions covered in global toxoid vaccines market report are North America, Europe, Asia-Pacific, Latin America and Rest of the World. On the basis of country level, the market of global toxoid vaccines is subdivided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, India, Japan, South East Asia, Middle East Asia (UAE, Egypt, Saudi Arabia) GCC, Africa, etc.
One of the major factors driving the growth of toxoid vaccines is increasing prevalence of tetanus and diphtheria. A toxoid vaccine utilized to avoid tetanus and diarrhea. Toxoid vaccination is used to prevent Pertussis, immunizations in pregnant ladies, and the common principles behind adult immunization. Tetanus and diphtheria vaccine helps to develop immunity to these diseases. For example; according to World Health Organization (WHO); about 38,000 people died from tetanus in 2017, globally. Thus, increasing number of tetanus and diphtheria will in turn boost the toxoid vaccine market growth. In addition, another factor supplementing the growth of global toxoid vaccine market is rising number of clinical trials of toxoid vaccines. For instance; as per the news published on February 28th, 2017, clinical study of new tetravalent (Type A, B, E, and F) botulinum toxoid vaccine derived from M Toxin was carried in Japan.M toxin is developed by novel tetravalent (type A, B, E, and F) botulinum toxoid.
Furthermore, growing number of supportive initiatives taken by the government regarding vaccination also drive the market growth. For instance; according to WHO in 2019; about 85% of infants globally (116 million infants) received 3 doses of diphtheria-tetanus–Pertussis-containing vaccines (DTP), sheltered against protecting them against infectious diseases which life-threatening and national DTP3 which is third dose of diphtheria 135 countries achieved coverage rate of 90% or above in 2019. Hence, initiatives by the government also drive the growth of the global toxoid vaccine in the forecast period. However, side effects caused by toxoid vaccines may hamper the growth of toxoid vaccine market. In spite of that, increasing number of research and development activities may offer more opportunities for the further growth of the market.
North America is expected to dominate the global toxoid vaccines market due to the increasing cases of tetanus and diphtheria, rising adoption of vaccines and growing research & development activities in this region. For instance; according to the Centers for Disease Control and Prevention (CDC); about 33 tetanus cases and two deaths were reported every year in the United States. In addition to that, five doses of DTaPas well asdiphtheria and Pertussis was made mandatory by the U.S. childhood immunization schedule as well as diphtheria and Pertussis, which is boosting the market growth. Furthermore, growing awareness and research and development in vaccines and rising focus to control the incidence and highly developed infrastructure augmenting the growth of the global toxoid vaccines market in this region.
Asia Pacific is the second-largest market for the global toxoid vaccines market due to the increasing population, supportive government initiatives for controlling disease and rising awareness about vaccines. For instance; according to ministry of health and family Welfare; in 2016 diphtheria outbreak in Kerala, nearly 79%cases occurred in 10 years age group. In addition to that, on August 15th, 2018, Tetanus Toxoid (TT) vaccine was replaced by a Tetanus and Diphtheria (Td) combination vaccine as guided by World Health Organization (WHO).
On December 8th, 2020; A new tetanus toxoid vaccine announced by Cipla in partnership with the Serum Institute of India. The vaccine can be used for prevention of tetanus in infants, children and adults. It will be distributed to hospitals and clinics in 5ml vials, which may deliver 10 doses each and last for up to 28 days once opened.
On January 14th, 2019; The U.S. Food and Drug Administration approved the expanded use of Adacel (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccine Adsorbed) to include repeat vaccination to help protect against tetanus, diphtheria and pertussis. It is now the first and only Tdap vaccine in the U.S. approved for a repeat dose in people 10 through 64 years of age 8 years or more after the first vaccination. Adacel is also the only Tdap vaccine available in a syringe made without natural rubber latex, which may help reduce risk to patients with an allergy.
|Historical data||2015 - 2020|
|Forecast Period||2021 - 2028|
|Market Size in 2021:||USD 4.97 Billion|
|Base year considered||2020|
|Forecast Period CAGR %:||
|Market Size Expected in 2028:||USD 6.81 Billion|
|Tables, Charts & Figures:||175|
|Toxoid Vaccines Companies||Serum Institute, Valeant Pharmaceuticals, GlaxoSmithKline Plc, Astellas Pharma Inc, Merck & Co. Inc, Pfizer Inc, Bharat Biotech, Emergent BioSolutions Inc, and others.|
|Segments Covered||By Type, By Indication, By Distribution Channel, By Application, By End-User|
|Regional Analysis||North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa|